Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
Leone D, Rodriguez A, Cowenhoven K, O’Connell M, Grossman M, Ferdman D. Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative. Pediatric Cardiology 2024, 1-9. PMID: 38300318, DOI: 10.1007/s00246-023-03388-3.Peer-Reviewed Original ResearchHigh-risk infantsPercentage of infantsRate of administrationPalivizumab administrationPalivizumab dosesRespiratory syncytial virus seasonHeart diseaseDose of palivizumabCongenital heart diseasePediatric cardiac patientsPalivizumab eligibilityEligible infantsPalivizumab treatmentVirus seasonPalivizumabHeart CenterCardiac patientsInfantsOxygen saturationDoseDiagnosis codesQuality improvement initiativesAdministrationBaseline rateMultidisciplinary team